Food Supplement, Health Product, Herbal Product or Drug? How SFDA Classifies Your Product

What counts as a food supplement under SFDA?

Under the SFDA Products Classification Guidance V9.0, a food supplement is defined as a food product "used to supplement the normal diet, which contain ingredients whether alone or in combination, that have a nutritional or physiological effect," available in "different forms of packaging." Typical components named in the definition include vitamins, minerals, fatty acids, amino acids, enzymes, prebiotics and probiotics, collagen, dietary fibres, melatonin, propolis, pollen, and herbs or food herbal extracts (V9 §1.7 Definitions, p.12; food-supplement category at §3.5). The umbrella regulation GSO 654 (Ed. 3, 2021), Foods for Special Dietary Use, and the technical standard SFDA.FD 55:2023, Food Supplements, sit behind that category.

That ingredient list is illustrative, not a licence. V9 opens its Food section with a hard gate: "food product must not contain any herb or ingredients with medicinal effect or medical claim" (p.22). So the presence of a "supplement-type" ingredient does not, by itself, keep a product on the food route. Four things can still move it off: the dose, the ingredient, a disease/medical claim, or a non-ingestible route — and V9 tells you which class each one leads to.

Why classification comes before registration

Classification is the decision that determines which SFDA sector, which regulation, and which registration pathway your product uses. Register as a food supplement and it goes through the Food sector under SFDA.FD 55:2023 (and GSO 654). Reach a health, herbal, or pharmaceutical outcome and the file belongs to the Drug sector pathway — the Implementing Regulation of the Law of Pharmaceutical and Herbal Establishments and Products — with different requirements, evidence, and timelines. These are different regulatory pathways inside one authority (SFDA), not different regulators.

In Mayar Vision's experience, misclassification is the most expensive early mistake in a market-entry project. A dossier assembled as a food supplement — with a food-style label, a food registration record, and a food Certificate of Analysis — cannot simply be re-badged if SFDA reclassifies it. It restarts. That is why the classification call should be made and documented before any artwork, testing, or dossier work begins.

The key quantitative test: total daily dose vs the SFDA.FD 55:2023 limit (form does not decide)

The most misunderstood rule in Saudi supplement classification is that the dosage form does not decide the category. V9 draws the food-vs-drug line by total daily dose: clause 4.1.1 classifies a product as a drug when it contains "one or more vitamins and/or minerals with concentrations above the upper concentration limit … calculated according to the product total daily dose (refer to SFDA.FD 55:2023)" — regardless of whether it is a tablet, a capsule, or a drink. This dose test is the key quantitative test, but it is applied alongside intended purpose, composition, claims, and route — not as the sole test.

V9 reinforces the point with worked, food-route daily caps for specific ingredients (clause 3.5.1, pp. 23–24). While a nutrient stays at or below its cap it can remain a food supplement; above it, the product moves off the food route (see the mapping below):

Source: SFDA Products Classification Guidance V9.0, cl. 3.5.1 (worked food-route caps). V9 also caps lozenge ingredients — menthol ≤ 5 mg/serving and ≤ 50 mg/day, eucalyptus oil < 0.5 mg/serving (cl. 3.4.7). The full per-nutrient maximum daily-dose limits for all vitamins and minerals live in SFDA.FD 55:2023 and GSO 2539 and are not reproduced here.

The practical consequence: you cannot classify — or register — at an artificially small serving size to duck a limit. SFDA looks at the product's genuine intended total daily intake. If the real daily dose crosses the SFDA.FD 55:2023 threshold, the product is a human pharmaceutical product, not a supplement, whatever the label says the serving is (V9 Note 4; cl. 4.1.1).

Is an oral product automatically a food supplement? (ingestion is necessary, not sufficient)

No — and this is the trap on the other side. A product that is not intended for ingestion cannot be an ordinary food supplement: V9 classifies a "food supplement Not intended for ingestion such as topicals, inhalers, suppositories..etc." as a human pharmaceutical product (cl. 4.1.19; Note 4, p.24). More broadly, a non-oral product does not qualify as a food supplement, and its correct class is determined under the applicable SFDA criteria; V9 lists the classic non-oral presentations as pharmaceutical — peritoneal dialysis solutions, solutions for hemofiltration and haemodiafiltration, saline and sterile water for IV injection, parenteral nutrition, injectable dosage forms, enema/rectal solutions, therapeutic radiopharmaceuticals, and medical gases (cl. 4.1.5–4.1.12, pp. 27–28).

But being ingestible is necessary, not sufficient. A swallowed product still has to pass three further tests to stay on the food route:

1. Dose — every nutrient's genuine total daily intake stays within the SFDA.FD 55:2023 limits (see above).
2. Ingredient — no active medicinal/pharmaceutical ingredient and no medicinal herb / herb used for a medical purpose.
3. Claims — no treatment, prevention, or diagnosis language. A disease claim is a classification trigger even with a familiar, food-grade ingredient — though, as the mapping below shows, a disease claim does not automatically make a product a pharmaceutical (claims are governed separately — see nutrition claims vs health claims).

So delivery cuts one way only: a non-ingestible route removes the food route immediately; ingestion merely keeps it open, pending the dose, ingredient, and claims tests.

Four possible outcomes when a proposed food supplement does not clearly meet the food route

When a proposed supplement fails one of the food-route tests, V9 does not default everything to "pharmaceutical." Its Note 4 (Food section, p.24) sets out exactly which trigger leads to which class. Each outcome is registered under a different SFDA sector / regulatory pathway:

Source: SFDA Products Classification Guidance V9.0 — Note 4 "Updates on Food Supplements Regulation" (p.24), the four-class tree in Chart 1 (p.9) and the §1.7 definitions (pp. 11–12), and Circular 1337 "Updating classification criteria for food supplement," cited by name inside Note 4.

Read the table as triggers, not as a formula. The three pharmaceutical triggers are firm: over the applicable limit, an active pharmaceutical or medicinal ingredient, or a non-ingestible pharmaceutical-type dosage form. The health-product route is different in kind — it is conditional, not automatic. A product that stays within the permitted limits and carries treatment, prevention, or diagnostic intent may fall into the health-product class, but only where it also satisfies SFDA's own health-product classification criteria. There is no one-to-one rule that "within the limit plus a disease claim always equals a health product." Any real classification decision has to be worked through the complete criteria in the current SFDA Products Classification Guidance, not settled from a summary table.

One row does deserve singling out, because a "swap the whole thing into the drug bucket" instinct gets it wrong: over the FD 55 limit → human pharmaceutical product. A dose above the limit is not a health-product halfway house — V9 classes it as a drug (Note 4; cl. 4.1.1).

The reason to keep these four apart is commercial as much as regulatory: each route has its own dossier, evidence bar, and processing reality, and moving between them mid-project means starting over. The boundary between food supplement and health / herbal / pharmaceutical is exactly the one the parent registration guide assumes you have already settled.

What pushes a product off the food route

Any one of these is enough to move a product out of the food-supplement category — you do not need all of them. Where V9 assigns a specific resulting class, it is named:

• Total daily dose above the SFDA.FD 55:2023 limit for a vitamin, mineral, or listed ingredient → human pharmaceutical product (V9 Note 4; cl. 4.1.1).
• An active medicinal / pharmaceutical ingredient → human pharmaceutical product (Note 4).
• A medicinal herb, or a herb used for a medical purpose → herbal product (Note 4; def. p.12).
• Treatment / prevention / diagnostic intent — on an otherwise food-compliant product this may lead to the health product class, where SFDA's health-product criteria are also met; it becomes a human pharmaceutical product where it additionally exceeds the applicable limit or contains an active pharmaceutical or medicinal ingredient (Note 4).
• A non-ingestible route — topical, inhaler, suppository, injectable, or similar → moves off the food route; a non-oral "food supplement" is classed as a human pharmaceutical product (Note 4; cl. 4.1.19), and specific non-oral presentations are enumerated at cl. 4.1.5–4.1.12.
• An intended-use or population profile that reads as medical rather than dietary — directions, warnings, and target user can reveal a purpose the product name hides.

A useful discipline is to run the finished product — its real formula, its genuine daily intake, its ingredients, and every claim on pack and online — against these triggers before committing to a category. When the route is settled and documented, the label, the GSO vs SFDA standard set, the Certificate of Analysis, and the claims can all be built to one coherent story — the thing that keeps a file from bouncing back. For the downstream label and import steps, see label-compliance basics and registration vs import clearance.

How Mayar Vision helps

Mayar Vision runs the classification decision as a defined first step in a supplement market-entry project: screening the finished formula and genuine total daily intake against the SFDA.FD 55:2023 dose logic, checking ingredients, claims, and route for triggers that move a product to a health, herbal, or pharmaceutical class, and documenting the classification rationale so the registration file is built on solid ground the first time.

Not sure whether your product is a food supplement or another class in Saudi Arabia? Send us the details for a preliminary classification review — product name, dosage form, full formulation with per-serving and per-day quantities, intended claims, and country of manufacture — and we will map the likely route and the major risks before you commit to artwork or testing. You can also see our food-supplement services.

Regulatory notice

This article provides general regulatory information based on public sources checked on 9 August 2026, principally the SFDA Products Classification Guidance, Version 9.0 (the current edition). It is not legal advice, an SFDA decision, or a substitute for a product-specific classification and review against the current applicable regulations, standards, and circulars. Classification criteria and standard editions can change; confirm the current position before submission, printing artwork, or shipping.